Tectonic Therapeutic, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Tectonic Therapeutics, Inc. reported a net loss of $25.2 million for the first quarter of 2026, with research and development expenses increasing significantly.
NASDAQ
Tectonic Therapeutic reports increased cash reserves and positive clinical trial data for TX45, despite ongoing net losses and rising R&D expenses in its Q3 2025 filing.
NASDAQ
Tectonic Therapeutic, Inc. reports significant progress in its TX45 and TX2100 clinical programs, bolstered by a $173.1 million private placement, despite ongoing net losses.
NASDAQ
10-Q: Tectonic Therapeutic Reports First Quarter 2025 Financial Results and Provides Business Update
Tectonic Therapeutic, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and financial position.
NASDAQ
Tectonic Therapeutic, following its merger with AVROBIO, reports a net loss of $17.7 million for the third quarter of 2024, while advancing its clinical programs.
NASDAQ
Tectonic Therapeutic, following its merger with AVROBIO, reports a net loss of $27.9 million for the first six months of 2024, alongside a significant increase in cash reserves.
NASDAQ
AVROBIO has halted its development programs and entered into a merger agreement with Tectonic Therapeutics, marking a significant strategic shift for the company.